

Lot #:

041323RB

Target value:0.200

### Acceptable Range (+/- 5%): 0.1900 to 0.2100

This whole blood control was tested against a five point calibration constructed from five NIST traceable calibrators.

Number of tests:	59
Average:	0.20067
Minimum Value:	0.1949
Maximum Value:	0.2062
Standard Deviation:	0.00191
Coefficient of Variation:	0.951%



Lot #:

092421JM

Target value:0.199

### Acceptable Range (+/- 5%): 0.1891 to 0.2090

This whole blood control was tested against a five point calibration constructed from five NIST traceable calibrators.

Number of tests:	49
Average:	0.19924
Minimum Value:	0.1954
Maximum Value:	0.2021
Standard Deviation:	0.00136
Coefficient of Variation:	0.681%



Lot #:

052920JM

Target value:0.198

### Acceptable Range (+/- 5%): 0.1881 to 0.2079

This whole blood control was tested against a five point calibration constructed from five NIST traceable calibrators.

Number of tests:	50
Average:	0.19877
Minimum Value:	0.1965
Maximum Value:	0.2036
Standard Deviation:	0.00165
Coefficient of Variation:	0.830%



Lot #:

021419JM

Target value:0.201

### Acceptable Range (+/- 5%): 0.1910 to 0.2111

This whole blood control was tested against a five point calibration constructed from five NIST traceable calibrators.

Number of tests:	51
Average:	0.20106
Minimum Value:	0.1958
Maximum Value:	0.2044
Standard Deviation:	0.00237
Coefficient of Variation:	1.180%



Lot #:

120117JM

Target value:0.200

### Acceptable Range (+/- 5%): 0.1900 to 0.2100

This whole blood control was tested against a five point calibration constructed from five NIST traceable calibrators.

Number of tests:	47
Average:	0.20016
Minimum Value:	0.1972
Maximum Value:	0.2028
Standard Deviation:	0.00140
Coefficient of Variation:	0.701%



Lot #:

120116JM

Target value:0.197

### Acceptable Range (+/- 5%): 0.1872 to 0.2069

This whole blood control was tested against a five point calibration constructed from five NIST traceable calibrators.

Number of tests:	48
Average:	0.19723
Minimum Value:	0.1950
Maximum Value:	0.1994
Standard Deviation:	0.00115
Coefficient of Variation:	0.582%



Lot #:

122915JM

Target value:0.199

### Acceptable Range (+/- 5%): 0.1891 to 0.2090

This whole blood control was tested against a five point calibration constructed from five NIST traceable calibrators.

Number of tests:	48
Average:	0.19931
Minimum Value:	0.1956
Maximum Value:	0.2023
Standard Deviation:	0.00161
Coefficient of Variation:	0.806%



Lot #:

011615JM

Target value:0.197

### Acceptable Range (+/- 5%): 0.1872 to 0.2069

This whole blood control was tested against a five point calibration constructed from five NIST traceable calibrators.

Number of tests:	62
Average:	0.19780
Minimum Value:	0.1952
Maximum Value:	0.2022
Standard Deviation:	0.00186
Coefficient of Variation:	0.939%



Lot #:

030714JM

Target value:0.198

### Acceptable Range (+/- 5%): 0.1881 to 0.2079

This whole blood control was tested against a five point calibration constructed from five NIST traceable calibrators.

Number of tests:	47
Average:	0.19803
Minimum Value:	0.1950
Maximum Value:	0.2012
Standard Deviation:	0.00177
Coefficient of Variation:	0.892%



Lot #:

042413JM

Target value:0.198

### Acceptable Range (+/- 5%): 0.1881 to 0.2079

This whole blood control was tested against a five point calibration constructed from five NIST traceable calibrators.

Number of tests:	51
Average:	0.19806
Minimum Value:	0.1941
Maximum Value:	0.2020
Standard Deviation:	0.00168
Coefficient of Variation:	0.847%



Lot #:

071012JM

Target value:0.196

### Acceptable Range (+/- 5%): 0.1865 to 0.2061

This whole blood control was tested against a five point calibration constructed from five NIST traceable calibrators.

Number of tests:	52
Average:	0.19626
Minimum Value:	0.1925
Maximum Value:	0.1986
Standard Deviation:	0.00130
Coefficient of Variation:	0.661%



Lot #:

091611JM

Target value:0.199

### Acceptable Range (+/- 5%): 0.1898 to 0.2097

This whole blood control was tested against a five point calibration constructed from five NIST traceable calibrators. The method of Headspace Gas Chromatography, Flame Ionization Detector (HS/GC/FID) was used to determine the target value and acceptable range (a minimum of 40 tests).

Number of tests:	40
Average:	0.19976
Minimum Value:	0.1973
Maximum Value:	0.2023
Standard Deviation:	0.00099
Coefficient of Variation:	0.494%



Lot #:

012711JM

Target value:0.196

### Acceptable Range (+/- 5%): 0.1862 to 0.2058

This whole blood control was tested against a five point calibration constructed from five NIST traceable calibrators. The method of Headspace Gas Chromatography, Flame Ionization Detector (HS/GC/FID) was used to determine the target value and acceptable range (a minimum of 40 tests).

Number of tests:	48
Average:	0.19667
Minimum Value:	0.1934
Maximum Value:	0.1995
Standard Deviation:	0.00135
Coefficient of Variation:	0.686%



Lot #:

081710JM

Target value: 0.200

### Acceptable Range (+/- 5%): 0.1900 to 0.2100

This whole blood control was tested against a five point calibration constructed from five NIST traceable calibrators. The method of Headspace Gas Chromatography, Flame Ionization Detector (HS/GC/FID) was used to determine the above results (a minimum of 40 tests).

Number of tests:	52
Average:	0.20069
Minimum Value:	0.1973
Maximum Value:	0.2030
Standard Deviation:	0.00143
Coefficient of Variation:	0.715%



Lot #:

031810JM

Target value:0.198

### Acceptable Range (+/- 5%): 0.1881 to 0.2079

This whole blood control was tested against a five point calibration constructed from five NIST traceable calibrators. The method of Headspace Gas Chromatography, Flame Ionization Detector (HS/GC/FID) was used to determine the above results (a minimum of 40 tests).

Number of tests:	48
Average:	0.19834
Minimum Value:	0.1947
Maximum Value:	0.2010
Standard Deviation:	0.00145
Coefficient of Correlation:	0.732%



Lot #:

082009JM

Target value: 0.193

### Acceptable Range (+/- 5%): 0.1834 to 0.2026

This whole blood control was tested against a five point calibration constructed from five NIST traceable calibrators. The method of Headspace Gas Chromatography, Flame Ionization Detector (HS/GC/FID) was used to determine the above results (a minimum of 40 tests).

Number of tests:	47
Average:	0.19333
Minimum Value:	0.1892
Maximum Value:	0.1972
Standard Deviation:	0.00177
Coefficient of Correlation:	0.917%

Procedural or assay modifications may alter the mean value obtained. Each laboratory should establish its own parameters of precision; use the mean assigned values and expected ranges d only as guidelines. 1q

#### ASSIGNED VALUES:

Level 1	Lot 50351 Exp. Date 02		
Method	Units	Mean	Expected Range
Gas Chromatography	mg/dL	82.5	74.3 - 90.8

18

Level 2		Lot 50352 Exp. Date 02/09	
Method	Units	Mean	Expected Range
Gas Chromatography	mg/dL	189	170 - 208

Level 3	Lot 50353 Exp. Date 02/09		
Method	Units	Mean	Expected Range
Gas Chromatography	mg/dL	285	256 - 314

#### REFERENCE

Baselt, R.C. Analytical Procedures for Therapeutic Drug Monitoring and Emergency Toxicology. Littleton, MA, PSG Publishing, 1987.

#### TECHNICAL ASSISTANCE

For technical assistance and ordering information call Central Coast Diagnostics, 888-534-0911, 805-534-0111, or FAX 805-534-1348

Mfg. by Clinical Controls Int'l, Los Osos, CA 93402.

LiquiSPx is a Trademark of SPxSystems, San Luis Obispo, CA, and is licensed to Clinical Controls.

#### CATALOG NUMBERS:

501 501-1	6X5 mL	TRI-LEVEL
501-2 501-3		LEVEL 2 LEVEL 3

Rev 02/05





### WHOLE BLOOD ETHANOL CONTROL

For in vitro diagnostic use Cat. No. 501, Levels 1, 2 & 3

#### INTENDED USE

Clinical Controls LiquiSP.<sup>TM</sup> Whole Blood Ethanol Control is an assayed quality control material intended for use in monitoring the accuracy and precision of the quantitative determination of ethanol in whole blood.

#### SUMMARY AND PRINCIPLE

This product is to be used exactly as directed for the patient sample in order to monitor, and thus minimize the potential for technical and performance errors in routine testing.

#### REAGENT DESCRIPTION

Clinical Controls LiquISP, Whole Blood Ethanol is prepared from stabilized normal human whole blood with the addition of ethanol. This product has been assigned lot-specific ethanol values using quantitative analytical methods. This product is packaged 5.0 mL per vial.

#### STORAGE AND STABILITY

Whole Blood Ethanoi Control is stable until the expiration date on the package and 45 days after opening when stored at 2-8°C. Discard any contaminated material. Microbial contamination is evidenced by an increase in turbidity and/or a characteristic odor.

#### PRECAUTIONS

This product is from human source material. Each unit of raw material used in its manufacture was tested by an FDA approved method and found to be negative by tests for antibodies to HIV, HVC, HBc, HTLV-I/II and nonreactive for HBsAg, STS, HCV RNA AND HIV-1 RNA. These methods, however, cannot offer total assurance that human source products will not transmit these diseases. Therefore, handle this product as potentially infectious in accordance with Good Laboratory Practices (GLP) and precautions.

This product contains small amounts of sodium azide, which may react with copper or lead plumbing to form explosive azides. Flush drain with copious amounts of water to prevent azide build up when disposing of residual product.

#### PROCEDURE

Allow the refrigerated controls to warm to room temperature (18-25° C) and gently swirl the control material prior to use in order to ensure product homogeneity.

#### LIMITATIONS

This material is a control for methods listed in the ASSIGNED VALUES section; it is not to be used as a calibrator. Accurate and reproducible results are dependent upon properly functioning instruments, reagents, standardization, and proper laboratory techniques. Individual laboratories may not obtain the mean assigned value as listed. If the values obtained do not fall within the expected range, call for technical assistance immediately.

#### VALUE ASSIGNMENT

The mean values and expected ranges printed in this insert were derived from extensive replicate analyses and are specific for this lot.

Values listed below were generated by Clinical Controls, the reagent/instrument manufacturer and/or independent laboratories in accordance with an established protocol. Individual laboratory means should fall within the corresponding expected range.

#### WHOLE BLOOD ETHANOL CONTROL

For *in vitro* diagnostic use Cat. No. 501, Levels 1, 2 or 3

Liquis

#### INTENDED USE

Clinical Controls LiquiSP<sup>TM</sup> Whole Blood Ethanol Control is an assayed quality control material intended for use in monitoring the accuracy and precision of the quantitative determination of ethanol in whole blood.

#### SUMMARY AND PRINCIPLE

This product is to be used exactly as directed for the patient sample in order to monitor, and thus minimize the potential for technical and performance errors in routine testing.

#### REAGENT DESCRIPTION

Clinical Controls LiquiSP<sub>x</sub> Whole Blood Ethanol is prepared from stabilized normal human whole blood with the addition of ethanol. This product has been assigned lot-specific ethanol values using quantitative analytical methods. This product is packaged 5.0 mL per vial.

#### STORAGE AND STABILITY

Whole Blood Ethanol Control is stable until the expiration date on the package and 45 days after opening when stored at 2-8° C. <u>This product</u> <u>may be stored frozen; however, it may be frozen and thawed one time only.</u> Discard any contaminated material. Microbial contamination is evidenced by an increase in turbidity and/or a characteristic odor.

#### PRECAUTIONS

This product is from human source material. Each unit of raw material used its manufacture was tested by an FDA approved method and found to be negative by tests for antibodies to HIV, HVC, HBc, HTLV-I/II and nonreactive for HBsAg, STS, HCV RNA AND HIV-1 RNA. These methods, however, cannot offer total assurance that human source products will not transmit these diseases. Therefore, handle this product as potentially infectious in accordance with Good Laboratory Practices (GLP) and precautions.

This product contains small amounts of sodium azide, which may react with copper or lead plumbing to form explosive azides. Flush drain with copious amounts of water to prevent azide build up when disposing of residual product.

#### PROCEDURE

Allow the refrigerated controls to warm to room temperature (18-25° C) and gently swirl the control material prior to use in order to ensure product homogeneity.

#### LIMITATIONS

This material is a control for methods listed in the ASSIGNED VALUES section; it is not to be used as a calibrator. Accurate and reproducible results are dependent upon properly functioning instruments, reagents, standardization, and proper laboratory techniques. Individual laboratories may not obtain the mean assigned value as listed. If the values obtained do not fall within the expected range, call for technical assistance immediately.

#### VALUE ASSIGNMENT

The mean values and expected ranges printed in this insert were derived from extensive replicate analyses and are specific for this lot.

Values listed below were generated by Clinical Controls, the eagent/instrument manufacturer and/or independent laboratories in accordance with an established protocol. Individual laboratory means should fall within the corresponding expected range. Procedural or assay modifications may alter the mean value obtained. Each laboratory should establish its own parameters of precision; use the mean assigned values and expected ranges provided only as guidelines.

#### ASSIGNED VALUES:

Level 2			ot 60742 Date 03/10
Method	Units	Mean	Expected Range
Gas Chromatography	mg/dL	196	180 – 212

#### REFERENCE

Baselt, R.C. Analytical Procedures for Therapeutic Drug Monitoring and Emergency Toxicology. Littleton, MA, PSG Publishing, 1987.

#### TECHNICAL ASSISTANCE

For technical assistance and ordering information call Central Coast Diagnostics, 888-534-0911, 805-534-0111, or FAX 805-534-1348

Mfg. by Clinical Controls Int'l, Los Osos, CA 93402.

LiquiSP<sub>x</sub> is a Trademark of SP<sub>x</sub>Systems, San Luis Obispo, CA, and is licensed to Clinical Controls.

#### CATALOG NUMBERS:

501-1	6X5 mL	LEVEL 1	
501-2	6X5 mL	LEVEL 2	
501-3	6X5 mL	LEVEL 3	



Proven stable in liquid format for four years.

Rev 06/06

### WHOLE BLOOD ETHANOL CONTROL

For *in vitro* diagnostic use Cat. No. 501, Levels 1, 2 or 3

#### INTENDED USE

Clinical Controls LiquiSP<sup>™</sup> Whole Blood Ethanol Control is an assayed quality control material intended for use in monitoring the accuracy and precision of the quantitative determination of ethanol in whole blood.

#### SUMMARY AND PRINCIPLE

This product is to be used exactly as directed for the patient sample in order to monitor, and thus minimize the potential for technical and performance errors in routine testing.

#### REAGENT DESCRIPTION

Clinical Controls LiquiSP<sub>x</sub> Whole Blood Ethanol is prepared from stabilized normal human whole blood with the addition of ethanol. This product has been assigned lot-specific ethanol values using quantitative analytical methods. This product is packaged 5.0 mL per vial.

#### STORAGE AND STABILITY

Whole Blood Ethanol Control is stable until the expiration date on the package and 45 days after opening when stored at 2-8° C. This product may be stored frozen; however, it may be frozen and thawed one time only. Discard any contaminated material. Microbial contamination is evidenced by an increase in turbidity and/or a characteristic odor.

#### PRECAUTIONS

This product is from human source material. Each unit of raw material used manufacture was tested by an FDA approved method and found to be tive by tests for antibodies to HIV, HVC, HBc, HTLV-I/II and nonreactive for HBsAg, STS, HCV RNA AND HIV-1 RNA. These methods, however, cannot offer total assurance that human source products will not transmit these diseases. Therefore, handle this product as potentially infectious in accordance with Good Laboratory Practices (GLP) and precautions.

This product contains small amounts of sodium azide, which may react with copper or lead plumbing to form explosive azides. Flush drain with copious amounts of water to prevent azide build up when disposing of residual product.

#### PROCEDURE

Allow the refrigerated controls to warm to room temperature (18-25° C) and gently swirl the control material prior to use in order to ensure product homogeneity.

#### LIMITATIONS

This material is a control for methods listed in the ASSIGNED VALUES section; it is not to be used as a calibrator. Accurate and reproducible results are dependent upon properly functioning instruments, reagents, standardization, and proper laboratory techniques. Individual laboratories may not obtain the mean assigned value as listed. If the values obtained do not fall within the expected range, call for technical assistance immediately.

#### VALUE ASSIGNMENT

The mean values and expected ranges printed in this insert were derived from extensive replicate analyses and are specific for this lot.

Values listed below were generated by Clinical Controls, the reagent/instrument manufacturer and/or independent laboratories in

rdance with an established protocol. Individual laboratory hs should fall within the corresponding expected range. Procedural or assay modifications may alter the mean value obtained. Each laboratory should establish its own parameters of precision; use the mean assigned values and expected ranges provided only as guidelines.

#### **ASSIGNED VALUES:**

Level 2		Lot 70932 Exp. Date 04/11	
Method	Units	Mean	Expected Range
Gas Chromatography	g/dL	0.182	0.166 - 0.198

#### REFERENCE

Baselt, R.C. Analytical Procedures for Therapeutic Drug Monitoring and Emergency Toxicology. Littleton, MA, PSG Publishing, 1987.

#### TECHNICAL ASSISTANCE

For technical assistance and ordering information call Central Coast Diagnostics, 888-534-0911, 805-534-0111, or FAX 805-534-1348

Mfg. by Clinical Controls Int'l, Los Osos, CA 93402.

LiquiSP<sub>x</sub> is a Trademark of SP<sub>x</sub>Systems, San Luis Obispo, CA, and is licensed to Clinical Controls.

#### CATALOG NUMBERS:

501-1	6X5 mL LEVEL 1	
501-2	6X5 mL LEVEL 2	
501-3	6X5 mL LEVEL 3	



Proven stable in liquid format for four years.

#### REVISED 02/08



#### WHOLE BLOOD ETHANOL CONTROL

For in vitro diagnostic use

Cat. No. 501, Levels 1, 2 or 3

#### INTENDED USE

Clinical Controls LiquiSP<sub>x</sub><sup>TM</sup> Whole Blood Ethanol Control is an assayed quality control material intended for use in monitoring the accuracy and precision of the quantitative determination of ethanol in whole blood.

#### SUMMARY AND PRINCIPLE

This product is to be used exactly as directed for the patient sample in order to monitor, and thus minimize the potential for technical and performance errors in routine testing.

#### REAGENT DESCRIPTION

Clinical Controls **LiquiSP**<sub>x</sub> Whole Blood Ethanol is prepared from stabilized normal human whole blood with the addition of ethanol. This product has been assigned lot-specific ethanol values using quantitative analytical methods. This product is packaged 5.0 mL per vial.

#### STORAGE AND STABILITY

Whole Blood Ethanol Control is stable until the expiration date on the package and 45 days after opening when stored at 2-8° C. <u>This product may be stored frozen;</u> however, it may be frozen and thawed one time only. Discard any contaminated material. Microbial contamination is evidenced by an increase in turbidity and/or a characteristic odor.

#### PRECAUTIONS

This product is from human source material. Each unit of raw material used in its manufacture was tested by an FDA approved method and found to be negative by tests for antibodies to HIV, HVC, HBc, HTLV-I/II and non-reactive for HBsAg, STS, HCV RNA AND HIV-1 RNA. These methods, however, cannot offer total assurance that human source products will not transmit these diseases. Therefore, handle this product as potentially infectious in accordance with Good Laboratory Practices (GLP) and precautions.

This product contains small amounts of sodium azide, which may react with copper or lead plumbing to form explosive azides. Flush drain with copious amounts of water to prevent azide build up when disposing of residual product.

#### PROCEDURE

Allow the refrigerated controls to warm to room temperature (18-25° C) and gently swirl the control material prior to use in order to ensure product homogeneity.

LIMITATIONS

Procedural or assay modifications may alter the mean value obtained. Each laboratory should establish its own parameters of precision; use the mean assigned values and expected ranges provided only as guidelines.

#### ASSIGNED VALUES:

		, I	ot 81692
Level 2		Ехр	. Date 11/12
Method	Units	Mean	Expected Range
Gas Chromatography	g/dL	0.190	0. <b>1</b> 84 – 0.195

#### REFERENCE

Baselt, R.C. Analytical Procedures for Therapeutic Drug Monitoring and Emergency Toxicology. Littleton, MA, PSG Publishing, 1987.

#### TECHNICAL ASSISTANCE

For technical assistance and ordering information call Central Coast Diagnostics, 888-534-0911, 805-534-0111, or FAX 805-534-1348

Mfg. by Clinical Controls Int'l, Los Osos, CA 93402.

LiquISP<sub>x</sub> is a Trademark of SP<sub>x</sub>Systems, San Luis Obispo, CA, and is licensed to Clinical Controls.

#### CATALOG NUMBERS:

501-1	6X5 mL LEVEL 1
501-2	6X5 mL LEVEL 2
501-3	6X5 mL LEVEL



3

Proven stable in liquid format for four years.

Cliniqa	New Lot 0902159c
NI022709	0.2034
NIOZZI 00	0.2037
	0.2043
	0.2031
	0.2045
	0.2027
	0.2034
abg030509	0.2029
abgeeeee	0.2063
	0.2057
	0.2065
	0.2091
	0.2067
	0.2053
	0.2059
	0.2053
jsh033009	0.2023
Jon 6666666	0.2031
	0.1993
	0.2014
	0.2028
	0.2022
	0.2001
	0.2015
	0.2009
jsh040809	0.2003
,	0.201
	0.2018
	0.2024
	0.2023
	0.2018
	0.2013
	0.2018
	0.2011
jm041409	0.1994
,	0.199
	0.199
	0.1975
	0.1997
	0.2006
	0.1992
	0.1975
Target (average)	0.202
sd	0.002607009
cv%	1.3
Range <u>+</u> 5% of Target	0.1919 to 0.2121

This whole blood control was tested against a five point calibration using five NIST traceable calibrators. The Phoenix Crime Laboratory uses the method of Headspace-Gas Chromatography, Flame Ionization Detector (HS/GC/FID) to determine the target concentration using a minimum of 40 results.

CUSTOM LIQUID CONTROLS & C RATORS . CLINIQA BRAND . OEM ULK . BIOCHEMICALS

### CERTIFICATE OF ANALYSIS Whole Blood Ethanol Control, Level 2, Labeled Vial



CATALOG NUMBER:	71036
LOT NUMBER:	0902159C
EXPIRATION DATE:	February 28, 2013
SOURCE:	Human Whole Blood
FORM:	Liquid, 1 mL fill
PRESERVATIVE:	< 0.1% Sodium Azide

**CONCENTRATIONS:** 

ANALYTE	METHOD	UOM
Ethanol	Gas Chromatography	194.2 mg/dL

HBsAg, anti-HIV 1/2, anti-HCV and HIV-1 Ag:

Nonreactive when tested on a single/pooled donor unit basis by FDA accepted methods.

STORAGE TEMPERATURE: 2-8°C

SHIPPING TEMPERATURE: 2-8°C

**SAFETY:** Because no test method can offer complete assurance that products derived from human source will not transmit infectious disease agents, it is recommended that this product be handled with the same precautions used for patient specimens.

QUALITY ASSURANCE APPROVAL 71036 C\_00 CO 7011 2/23/09

DATE

2/24/09 Reed UBV A53320

Toll Free • 800.728.5205 Phone • 760.744.1900 Fax • 760.571.5197 Web • www.cliniqa.com Cliniqa Corporation • 288 Distribution St. • San Marcos, CA 92078 USA



# Whole Blood Ethanol Control Level 2

#### INTENDED USE

FOR IN VITRO DIAGNOSTIC USE

Clinical Controls LiquiSP<sub>x</sub><sup>TM</sup> Whole Blood Ethanol Control is an assayed quality control material intended for use in monitoring the accuracy and precision of the quantitative determination of ethanol in whole blood.

Œ

#### SUMMARY AND PRINCIPLE

This product is to be used exactly as directed for the patient sample in order to monitor, and thus minimize the potential for technical and performance errors in routine testing.

#### PRODUCT DESCRIPTION

Clinical Controls LiquiSP<sub>e</sub> Whole Blood Ethanol is prepared from stabilized normal human whole blood with the addition of ethanol. This product has been assigned lot-specific ethanol values using quantitative analytical methods. This product is packaged 5.0 mL per vial.

#### STORAGE AND STABILITY

Whole Blood Ethanol Control is stable until the expiration date on the package and 45 days after opening when stored at 2-8° C. <u>This product</u> <u>may be stored frozen; however, it may be frozen and thawed one time</u> <u>only.</u> Discard any contaminated material. Microbial contamination is evidenced by an increase in turbidity and/or a characteristic odor.

#### PRECAUTIONS

### Human source material. Treat as potentially infectious.

Each serum/plasma donor unit used in the manufacture of this product has been tested by FDA accepted methods and found non-reactive for the presence of HBsAg and antibody to HIV-1/2, HCV and HIV-1 Ag.

Vhile these methods are highly accurate, they do not guarantee that all fected units will be detected. Because no known test method can offer complete assurance the hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV) or other infectious agents are absent, all products containing human source material should be considered potentially infectious and handled with the same precautions used with patient specimens.

This product contains 0.09% sodium azide as a preservative. Sodium azide may react with lead and copper plumbing to form potentially explosive compounds. Flush with excess water upon disposal.

MANUFACTURED BY CLINIQA CORPORATION 288 Distribution St. San Marcos, CA 92078 USA SALES AND TECHNICAL SUPPORT P: 800 728 5205 +1 760 744 1900 F: +1 760 891 3767

www.cliniga.com

#### PROCEDURE

Allow the refrigerated controls to warm to room temperature (18-25° C) and gently swirl the control material prior to use in order to ensure product homogeneity.

#### LIMITATIONS

This material is a control for methods listed in the ASSIGNED VALUES section; it is not to be used as a calibrator. Accurate and reproducible results are dependent upon properly functioning instruments, reagents, standardization, and proper laboratory techniques. Individual laboratories may not obtain the mean assigned value as listed.

#### VALUE ASSIGNMENT

The mean values and expected ranges printed in this insert were derived from extensive replicate analyses and are specific for this lot.

Values listed below were generated by Cliniqa, the reagent/instrument manufacturer and/or independent laboratories in accordance with an established protocol. Individual laboratory means should fall within the corresponding expected range.

Procedural or assay modifications may alter the mean value obtained. Each laboratory should establish its own parameters of precision; use the mean assigned values and expected ranges provided only as guidelines.

#### ASSIGNED VALUES

Level 2		Lot No.: XR2829 Exp. Date: 2013/01	
Method	Units	Mean	Expected Range
Gas Chromatography	mg/dL	197.5	190-205

#### REFERENCES

FOR ORDERS AND

CUSTOMER SERVICE

F: +1 760 571 5197

800 728 5205

+1 760 744 1900

Baselt, R.C. Analytical Procedures for Therapeutic Drug Monitoring and Emergency Toxicology Littleton, MA, PSG Publishing, 1987.

### RE-ORDER INFORMATION Whole Blood Ethanol Control

P-

Catalog No. **REF** 93211 Level 1, 6 x 5 mL

Catalog No. REF 93212 Level 2, 6 x 5 mL

Catalog No. REF 93213 Level 3, 6 x 5 mL



EC RESPONSIBLE AUTHORITY

CEpartner4U

Esdoomlaan 13

3951 DB Maarn, The Netherlands

P: +31 343 442 524

F: +31 343 442 162